Evidence map›Paper›PMID 41693972›Full record

SynthesisWorld journal of gastroenterology2026

Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma.

Kyle R Stephens, Megan Wilson, Manting Xu, Jeremy T Gaskins, Gina Genova, Robert C G Martin Ii

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kyle R StephensDivision of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, Louisville, KY 40202, United States.
Megan WilsonDivision of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, Louisville, KY 40202, United States.
Manting XuDepartment of Radiology, University of Louisville, Louisville, KY 40202, United States.
Jeremy T GaskinsDepartment of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY 40202, United States.
Gina GenovaKornhauser Health Sciences Library, University of Louisville, Louisville, KY 40202, United States.
Robert C G Martin IiDivision of Surgical Oncology, Hiram C Polk Jr, MD, Department of Surgery, University of Louisville, Louisville, KY 40202, United States. robert.martin@louisville.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate prediction of hepatocellular carcinoma (HCC) recurrence after curative therapy remains challenging. Mac-2 binding protein glycosylation isomer (M2BPGi), a serum marker of liver fibrosis, may serve as a noninvasive prognostic biomarker.

aimTo evaluate the association between preoperative M2BPGi levels and HCC recurrence following curative treatment.

methodsWe searched PubMed Cochrane CENTRAL, EMBASE, and BIOSIS Citation Index for English-language studies in humans reporting HCC recurrence outcomes stratified by high

resultsHigh preoperative M2BPGi was significantly associated with increased recurrence risk. The pooled unadjusted HR was 2.98 (95%CI: 1.50-5.91;

conclusionPreoperative serum M2BPGi is a promising biomarker for HCC recurrence after hepatectomy. Its strong association with risk, minimal heterogeneity across studies, and ease of measurement support its potential clinical utility.

Indexed as

Antigens, NeoplasmBiomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsMembrane GlycoproteinsNeoplasm Recurrence, LocalGlycosylationHepatectomyHumansPrognosisProgression-Free SurvivalRetrospective StudiesAntigens, NeoplasmBiomarkers, TumorMembrane GlycoproteinsTAA90K protein, humanBiomarkerHepatocellular carcinomaMac-2 binding protein glycosylation isomerRecurrenceSerum

Identifiers

PMID41693972
PMCPMC12897514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.